Zycus Named a LEADER in 2025 IDC MarketScape for Source-to-Pay
7.7.2025 16:41:00 EEST | Business Wire | Press release
Zycus, a global leader in AI-powered procurement technology, has been named a Leader in the IDC MarketScape: Worldwide AI-Enabled Source-to-Pay 2025 Vendor Assessment.
This recognition follows a comprehensive evaluation, including RFI submissions, live product demos, analyst briefings, and customer interviews.
“Zycus is a recognized Leader in the Source-to-Pay space leveraging Agentic AI to drive procurement transformation. With AI agents like Merlin Intake and the Autonomous Negotiation Agent (ANA), Zycus offers a seamlessly integrated solution suite for enterprises focused on cost savings, risk mitigation, and scalability,”
— Patrick Reymann, Research Director, IDC
“We believe this recognition underscores our commitment to empowering procurement teams through Merlin Agentic Platform, deep domain expertise, and customer-first innovation,” said Aatish Dedhia, Founder & CEO, Zycus. “With a global product footprint spanning every aspect of the S2P lifecycle, Zycus is proud to support enterprises worldwide in achieving procurement excellence.”
The report acknowledges Zycus’s strengths in:
- AI-Driven Automation and Compliance: Zycus leverages GenAI, Agentic AI and advanced automation to streamline invoice-to-PO, contract, and receipt validation, supporting 2-way, 3-way, and 4-way matching. The platform’s AI-driven anomaly detection flags pricing mismatches, duplicate invoices, and policy violations, enhancing compliance and reducing manual intervention.
- Customer Support: Users express broad satisfaction with customer support and find the Zycus support infrastructure to be responsive and attentive. Zycus' Voice of theCustomer program is an innovative approach that drives actionable insights to shape product development.
The report further states:
“Buyers should consider Zycus when seeking a mature, AI-powered, and forward-thinking S2P platform that delivers robust automation, compliance, and supplier collaboration. Zycus is particularly well-suited for mid-sized to large multinational organizations aiming to digitize procurement, enforce policy compliance, and drive efficiency across the full S2P lifecycle.”
Integrated Source-to-Pay Platform
Zycus provides a modular suite covering procurement, eInvoicing, spend analysis, supplier and contract management, and sourcing. The platform integrates seamlessly with leading ERP and finance systems, offering bi-directional sync and customizable workflows.
For more information on Zycus’ Source-to-Pay Suite and its position in IDC MarketScape, click here.
About IDC MarketScape
IDC MarketScape’s vendor assessment model is designed to provide an overview of the competitive fitness of technology and service providers in a given market. The research methodology employs a rigorous scoring system based on both qualitative and quantitative criteria, resulting in a single graphical illustration of each vendor’s position.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250702493109/en/
Contacts
Pooja Newar
Senior Marketing Manager
Pooja.newar@zycus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom